Our mission is to develop a radically new approach for the treatment of severe, chronic autoimmune diseases.
From start on, a major goal of INNODIA was to undertake clinical intervention studies and to pave the way for the development of novel treatments to prevent and cure Type 1 Diabetes.
INNODIA is now performing mechanistic-based clinical studies, using a Master-Protocol established within INNODIA.
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
• Imcyse and Pfizer to collaborate to develop Imotope™ candidates to potentially treat Rheumatoid Arthritis
• Pfizer to lead clinical development and commercialization activities
• Imcyse to receive upfront payment in cash and through the purchase of equity in addition to milestone up to $180 million and tiered royalty payments
Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active, specific immunotherapies for the treatment of severe, chronic autoimmune diseases, today announced Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes.
Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options.
Liège, Belgium, January 08, 2021 – More info here
Page 1 of 3
Headquarters:
Avenue Pré-Aily 14
4031 Liège (Angleur)
BELGIUM
Phone : +32 (0)4 325 1100
 |
 |
|
© Imcyse 2021 - All rights reserved |
|